TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Patient decisional regret
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Child attention regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child emotion regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic value of serum cathepsin S and chromogranin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensitivity and specificity of methylation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total recovery of radioactivity in excrement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of unchanged drug and metabolites in plasma, urine, and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum concentration) parameters of TRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EORTC QLQ CIPN20 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in Brief Assessment of Social Skills-Dementia (BASS-D)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from baseline in Telephone Interview for Cognitive Status (TICS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in Telephone-based Mini-Mental State Examination (I-TEL-MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Melbourne Assessment of Unilateral Upper Limb Function (MUUL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABILHAND-Kids
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of hypozincemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation between hypozincemia and urea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation between hypozincemia and S. Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation between hypozincemia and eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Short Form 36 Health Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mucositis toxicity rates
Endpoint domain: Adverse events/effects
Primary endpoint: World Health Organization Quality of life (WHO QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of the exercise capacity from baseline to 8 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the peripheral muscle strength from baseline to 8 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of the upper extremity exercise capacity from baseline to 8 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intracerebral concentrations of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average strength of urges
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average probability of controlling urges
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of albumin-corrected hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative recovery of gastrointestinal (GI) function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Level of knowledge on thalassemia
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitude towards thalassemia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Practice towards thalassemia
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility measured by the number of subjects accrued to the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility measured by the number of subjects to complete the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Residual control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abdominal circumference measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Iowa Infant Feeding Attitude Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of dose adjustment or discontinuation due to NK cell toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of subjects with Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Children's State Anxiety and Children's Fear Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PedsQL Health Care Satisfaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline to Week 8 on the Cohen-Mansfield Agitation Inventory (CMAI) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of MSE-ERCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adverse event rate of MSE-ERCP
Endpoint domain: Adverse events/effects
Primary endpoint: Time to diagnosis and/or treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Inequalities in treatments received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Histological effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crude Adequate Clinical and Parasitological Response (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients With Treatment Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Patients With Clinically Significant Abnormal Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New chronic medical conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Local Reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Left Ventricular Eccentricity Index (LVEI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Restoration Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability score for RA-ILD screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of RA-ILD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological features of RA-ILD on HRCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar ridge changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in accuracy on affective prosody expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in accuracy on affective prosody recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in resting state functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in PROMIS-29 Physical Health Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: booster take-up in 2 weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: booster take-up in 4 weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence rate of pneumothorax
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Score of Satisfaction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Completed PrEP Consultations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Emotion dysregulation severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Main trial endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DASH Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Acceptability of Workbook
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Genetic Counselor Acceptability of Workbook
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time until return of motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time from spoke CT/CTA to door-out for transfer patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from Hub door to groin puncture for non-transfer patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Wound Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for fexinidazole and metabolites M1, M2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for fexinidazole and metabolites M1, M2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Heart Failure Hospital Readmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decline in Health-related Quality of Life (HRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diagnostic value of 68Ga PSMA PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Major Device Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Heart Rate Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of hemolytic hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Pain and Disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Labour market participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction of hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Reduction of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: estimated blood loss in mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: operative time in HH:MM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PROMIS-Pain interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PROMIS-Pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Probability of Progression to Pulmonary Fibrosing-Interstitial Lung Disease (PF-ILDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hernia specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence and severity of local and systemic adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Pf blood-stage infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dengue seroprevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Surgical site swelling and bruising
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quality of caregiving capacity
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Performance-based EF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response in patients after 6 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tonsil size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of practice head impacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of practice head acceleration events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practice head impact rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change from Baseline in Indication-Specific Total Countable Seizures as Recorded by Caregivers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: General Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hammersmith Neonatal Neurological Examination (HNNE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median response rate to text messages
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall median score on the System Usability Scale (SUS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall score on the Acceptability of Intervention Measure (AIM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite of all-cause mortality or all stroke
Endpoint domain: Mortality/survival
Primary endpoint: Shear stress measured in mPa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of Orelabrutinib and MTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in MFI General Fatigue Domain Score at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Hippocampal synaptic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patients alive and free of any worsening features
Endpoint domain: Mortality/survival
Primary endpoint: Signs of improvements (IMAGING or ARRHYTMIC improvements)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRS ≤ 2 at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acquisition of tolerance to non-heated cow's milk proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physicians Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term outcomes of Odontoid fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of VR treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of VR treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in overall treatment experience satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain management during subcutaneous injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in SALT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean change from baseline in VASI measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Surgical assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in CK in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in delayed onset of muscle soreness (DOMS) in the knee flexors (KF) and extensors (KE) of both limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in squat jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum average lateral center of mass (COM) excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving EASI-75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as Assessed by Quantification of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Kansas City Cardiomyopathy Questionnaire - Total Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of post-contrast acute kidney injury (PC-AKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of long-term decline in renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Efficacy of axitinib in addition to nivolumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intelligence quotient (IQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age of development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to apply the tactical tourniquet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Impact of pelvic floor disorders on sexual function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Bleeding Index (BI) at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discontinuation of selumetinib
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of imaginal exposures made by the participant during the treatment period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of in vivo exposures made by the participant during the treatment period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to the treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Participants satisfaction with treatment, assessed by The Client Satisfaction Questionnaire (CSQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evolution of the sensory and affective components of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Targeted PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of eating self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of physical activity self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Range of Motion Measured by a Goniometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of unapposed stent struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minimal luminal stent area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minimal lumen stent diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PCL-5 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neuro Recovery Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of DZD9008
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum plasma concentration (tmax) of DZD9008
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased condom use among stable sexual partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent changes from baseline in power (dB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent changes from baseline in rates of interictal spikes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent changes from baseline in rates of high frequency oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent changes in connectivity density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Transcranial Magnetic Stimulation Combined Electroencephalography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Feasibility measured by participant completion rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnostic accuracy of CT-FFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Single leg standing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment of the lower extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinetti Fall Activity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSMA Uptake in PSMA Positive Tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PSMA Uptake in PSMA Negative Tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants on Treatment with DRF
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: First session technical success for biliary access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes